País: Singapur
Idioma: inglés
Fuente: HSA (Health Sciences Authority)
Inactivated Poliomyelitis Virus Type 1 (Mahoney); Inactivated Poliomyelitis Virus Type 2 (MEF-1); Inactivated Poliomyelitis Virus Type 3 (Saukett)
SANOFI-AVENTIS SINGAPORE PTE. LTD.
J07BF03
8 D.U.
INJECTION
Inactivated Poliomyelitis Virus Type 1 (Mahoney) 40 D.U./0.5 mL; Inactivated Poliomyelitis Virus Type 2 (MEF-1) 8 D.U./0.5 mL; Inactivated Poliomyelitis Virus Type 3 (Saukett) 32 D.U./0.5 mL
SUBCUTANEOUS, INTRAMUSCULAR
Prescription Only
SANOFI PASTEUR
ACTIVE
1999-01-06
IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) SUSPENSION FOR INJECTION IN A PREFILLED SYRINGE READ THIS ENTIRE LEAFLET CAREFULLY BEFORE GETTING VACCINATED. Keep this leaflet until you have completed the entire vaccination regimen. You might need to read it again. Follow the advice of your doctor or nurse carefully. If you need more information or advice, ask your doctor or nurse. Make sure to complete the entire vaccination regimen. If you do not, you may not be completely protected. The vaccine has been prescribed for you. Do not pass it on to others. THE ACTIVE SUBSTANCES ARE: One dose (0.5 ml) contains Poliovirus # type 1, Mahoney strain (inactivated) . . . . . . . . . . . . . . .40 DU*† Poliovirus # type 2, MEF-1 strain (inactivated) . . . . . . . . . . . . . . . . . . . 8 DU*† Poliovirus # type 3, Saukett strain (inactivated) . . . . . . . . . . . 32 DU*† This vaccine is in compliance with European Pharmacopoeia requirements and WHO recommendations. # cultured on VERO cells * DU: D-antigen Unit † or the equivalent antigenic quantity, determined by suitable immunochemical method. THE OTHER INGREDIENTS ARE: 2-phenoxyethanol, ethanol, formaldehyde, medium 199 Hanks (containing in particular amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injections), hydrochloric acid or sodium hydroxide for pH adjustment. PRODUCT OWNER: SANOFI PASTEUR SA - 2, avenue Pont Pasteur - 69007 LYON 1. WHAT IMOVAX POLIO IS AND WHAT IT IS USED FOR IMOVAX POLIO is presented in the form of a suspension for injection (0.5 ml) in a prefilled syringe with an attached needle or with two separate needles – box of 1 or 20. This vaccine is indicated for the prevention of poliomyelitis in infants, children a Leer el documento completo
SG/IMO/0423/SPC0722 _ _ _1_ _ _ NAME OF THE MEDICINAL PRODUCT IMOVAX POLIO, SUSPENSION FOR INJECTION IN PREFILLED SYRINGE POLIOMYELITIS VACCINE (INACTIVATED) QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 mL) contains: Poliomyelitis virus (inactivated) Type 1 (Mahoney strain)#..............................................................................................................40 DU* + Type 2 (MEF-1 strain)# ....................................................................................................................8 DU* + Type 3 (Saukett strain)# ................................................................................................................32 DU* + This vaccine complies with European Pharmacopoeia requirements and WHO recommendations. # produced on VERO cells * DU: D-antigen unit + or equivalent antigenic quantity determined by a suitable immunochemical method. IMOVAX POLIO may contain traces of neomycin, streptomycin and polymyxin B (see section Contraindications). Excipients with known effect: Phenylalanine………………………………………………………………………………….12.5 micrograms Ethanol………………………………………………………………………………………………2 milligrams (See section Special warnings and precautions for use). For the full list of excipients, see section List of excipients. PHARMACEUTICAL FORM Suspension for injection in prefilled syringe. IMOVAX POLIO is a clear and colourless suspension. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination. IMOVAX POLIO must be used according to effective official recommendations. POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY • From the age of 2 months, 3 successive doses of 0.5 mL of IMOVAX POLIO should be administered at intervals of one or two months, followed by a first booster 12 months after the last dose. • _For subsequ Leer el documento completo